Organon & Co. Aktie News

Organon & Co. faces ongoing challenges, with shares down over 75% since debut and recent CEO resignation after inventory probe. OGN Q3 results show stagnant revenues, declining Women's Health sales, and persistent high debt, despite low valuation metrics like a 3.7x forward P/E. Dividend has been slashed, Nexplanon sales fell 50% in the US in Q3, and the company is selling assets to manage leve...

Organon & Co. ( OGN ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Jennifer Halchak - Head of Investor Relations Carrie Cox Joseph Morrissey - Interim CEO & Executive VP and Head of Manufacturing & Supply Matthew Walsh - Executive VP & CFO Conference Call Participants Jason Gerberry - BofA Securities, Research Division David Amsellem - Piper Sandler & Co., Research D...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2025. “I am humbled to be working alongside our talented team during this pivotal time for Organon,” said Joe Morrissey, Organon's Interim Chief Executive Officer. “We are harnessing the company's many strengths, including a diverse portfolio that we expect will generate...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon divests the JADA System for up to $465 Million to Laborie.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to announce Q3 2025 financial results on November 10, 2025.

Organon & Co. shares plunged Monday, October 27th, after CEO Kevin Ali resigned amid an audit committee investigation into wholesaler sales irregularities. Despite the scandal, OGN's valuation at $7 per share is extremely cheap compared to peers, with a diversified product portfolio and global reach. The main risk is OGN's heavy $8.3 billion net debt load, which could hinder share price recover...

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- On October 27, 2025, investors in Organon & Co. (NYSE: OGN) saw the price of their shares plummet $2.10 (-23%) after the company announced the findings of its Audit Committee's investigation into improper wholesale sales practices for Nexplanon and CEO Kevin Ali's resignation.

Organon said on Monday CEO Kevin Ali will resign from his role and be replaced by Joseph Morrissey on an interim basis, after an internal investigation into wholesaler sales practices for its Nexplanon contraceptive implant.